Literature DB >> 2831308

Childhood giant axonal neuropathy. Case report and review of the literature.

R Tandan1, B W Little, E S Emery, P S Good, W W Pendlebury, W G Bradley.   

Abstract

Giant axonal neuropathy (GAN) is a rare autosomal recessive childhood disorder characterized by a peripheral neuropathy and features of central nervous system involvement. Typically seen are distal axonal swellings filled with 8-10 nm in diameter neurofilaments in central and peripheral axons, and intermediate filament collections in several other cell types. Many neurotoxins produce a morphologically similar neuropathy in humans and experimental animals. Defective nerve fiber energy metabolism has been postulated as a cause in these toxic neuropathies. It is possible that GAN represents an inborn error of metabolism of enzyme-linked sulfhydryl containing proteins, resulting in impaired production of energy necessary for the normal organization of intermediate filaments.

Entities:  

Mesh:

Year:  1987        PMID: 2831308     DOI: 10.1016/0022-510x(87)90019-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Giant axonal neuropathy: report on a case with focal fiber loss.

Authors:  M Sabatelli; E Bertini; S Servidei; E Fernandez; S Magi; P Tonali
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Giant axonal neuropathy (GAN): an immunohistochemical and ultrastructural study report of a Latin American case.

Authors:  A L Taratuto; G Sevlever; M Saccoliti; L Caceres; M Schultz
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

3.  Giant axonal neuropathy: a rare inherited neuropathy with simple clinical clues.

Authors:  Mahesh Kamate; Shashikala Ramakrishna; Shweta Kambali; Anita Mahadevan
Journal:  BMJ Case Rep       Date:  2014-09-12

4.  Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy.

Authors:  Rachel M Bailey; Diane Armao; Sahana Nagabhushan Kalburgi; Steven J Gray
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.